Clinical Trial Update: Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial [Phase 3]

View source ↗

Summary

The update concerns the Phase 3 OCEAN(a) outcomes trial evaluating olpasiran to reduce lipoprotein(a)-driven cardiovascular events in patients with atherosclero…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease

Drugs mentioned

• Olpasiran (olpasiran)

Snippet

Sponsor: Amgen | Conditions: Atherosclerotic Cardiovascular Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING